Pharmacology and clinical experience with amprenavir.

about

Pharmacology and clinical experience with amprenavir.

Item

http://www.wikidata.org/entity/Q45093857

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh-hant

name

Pharmacology and clinical experience with amprenavir.

@en

Pharmacology and clinical experience with amprenavir.

@nl

type

Item

label

Pharmacology and clinical experience with amprenavir.

@en

Pharmacology and clinical experience with amprenavir.

@nl

prefLabel

Pharmacology and clinical experience with amprenavir.

@en

Pharmacology and clinical experience with amprenavir.

@nl

P1476

Pharmacology and clinical experience with amprenavir.

@en

P2093

Conway B

http://www.w3.org/2001/XMLSchema#string

Shafran SD

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

Decay characteristics of HIV-1-infected compartments during combination therapy

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors.

P304

371-382

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.9.2.371

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2000-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11060683

http://www.w3.org/2001/XMLSchema#string